SCHEMBL2798052

SCHEMBL2798052

N#CC1(CCOCc2ccccc2)CCC2(CC1)OCCO2

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 8/20 0.38
TSHR P16473 2/20 0.36
ALDH1A1 P00352 1/20 0.36
NAAA Q02083 1/20 0.34
KDM1A O60341 1/20 0.34
CHRM2 P08172 2/20 0.33
CHRM1 P11229 2/20 0.33
SLC6A2 P23975 1/20 0.33
PDE4A P27815 1/20 0.33
SLC6A4 P31645 1/20 0.33
OPRM1 P35372 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSK P43235 1/20 0.33
TACR1 P25103 1/20 0.33
LTA4H P09960 1/20 0.33
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26863061 0.89 TSHR (0.45) CHRM3TSHRALDH1A1NAAAKDM1A
SCHEMBL31721423 0.86 TACR1 (0.40) CHRM3TSHRALDH1A1KDM1ACTSL
SCHEMBL20288108 0.85 CHRM3 (0.40) CHRM3TSHRALDH1A1NAAACHRM2
SCHEMBL30788912 0.83 KDM1A (0.43) CHRM3TSHRALDH1A1NAAAKDM1A
SCHEMBL1550740 0.79 KDM1A (0.39) TSHRALDH1A1KDM1AOPRM1
SCHEMBL20267508 0.77 CHRM3 (0.39) CHRM3TSHRALDH1A1NAAACHRM2
SCHEMBL13234474 0.76 TSHR (0.36) CHRM3TSHRALDH1A1NAAACHRM2
SCHEMBL2150078 0.76 TACR1 (0.40) TSHRALDH1A1TACR1GRIN1GRIN2B
SCHEMBL31721613 0.75 NAAA (0.35) TSHRNAAAOPRM1CTSLCTSB
SCHEMBL26688770 0.74 TSHR (0.48) CHRM3TSHRALDH1A1NAAACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-08-23 US disclosed
EP-2468743-A1 Nitrogen-containing bicyclic compounds useful as antibacterial agents Toyama Chemical Co., Ltd. (JP) 2012-06-27 EP disclosed
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2010-07-01 US disclosed
EP-1900732-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2008-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF ROS1, NOX1, ARG1 CHRM3 2053/4885TSHR 1204/4885ALDH1A1 2925/4885
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION NQO2, ASNS, NDUFS1 CHRM3 4678/4885TSHR 4692/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.